147 related articles for article (PubMed ID: 2344162)
1. Antimicrobial activity and stability to beta-lactamase of BMY-28271, a new oral cephalosporin ester.
Matsui H; Hiraoka M; Inoue M; Mitsuhashi S
Antimicrob Agents Chemother; 1990 Apr; 34(4):555-61. PubMed ID: 2344162
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity and beta-lactamase stability of the oral cephalosporin BMY-28100.
Hiraoka M; Masuyoshi S; Tomatsu K; Inoue M; Mitsuhashi S
Eur J Clin Microbiol; 1987 Oct; 6(5):559-63. PubMed ID: 3501756
[TBL] [Abstract][Full Text] [Related]
3. In vitro antibacterial activity and beta-lactamase stability of SY5555, a new oral penem antibiotic.
Inoue E; Mitsuhashi S
Antimicrob Agents Chemother; 1994 Sep; 38(9):1974-9. PubMed ID: 7811005
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo evaluations of a new broad-spectrum oral cephalosporin, BMY-28232, and its prodrug esters.
Tomatsu K; Masuyoshi S; Hirano M; Kawaguchi H; Oki T; Fung-Tomc J; Desiderio JV; Kessler RE
Antimicrob Agents Chemother; 1989 Apr; 33(4):489-97. PubMed ID: 2786371
[TBL] [Abstract][Full Text] [Related]
5. BMY-28100, a new oral cephalosporin: antimicrobial activity against nearly 7,000 recent clinical isolates, comparative potency with other oral agents, and activity against beta-lactamase producing isolates.
Jones RN; Barry AL
Diagn Microbiol Infect Dis; 1988 Jan; 9(1):11-26. PubMed ID: 3259489
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological activity of a new cephalosporin, BMY-28232 and its prodrug-type esters for oral use.
Kamachi H; Narita Y; Okita T; Abe Y; Iimura S; Tomatsu K; Yamasaki T; Okumura J; Naito T; Oki T
J Antibiot (Tokyo); 1988 Nov; 41(11):1602-16. PubMed ID: 3198494
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo antibacterial activities of ME1207, a new oral cephalosporin.
Tamura A; Okamoto R; Yoshida T; Yamamoto H; Kondo S; Inoue M; Mitsuhashi S
Antimicrob Agents Chemother; 1988 Sep; 32(9):1421-6. PubMed ID: 3264132
[TBL] [Abstract][Full Text] [Related]
8. The activity of BMY 28142 a new broad spectrum beta-lactamase stable cephalosporin.
Neu HC; Chin NX; Jules K; Labthavikul P
J Antimicrob Chemother; 1986 Apr; 17(4):441-52. PubMed ID: 3486862
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the in vitro and in vivo antibacterial activities of cefepime (BMY-28142) with ceftazidime, cefuzonam, cefotaxime and cefmenoxime.
Masuyoshi S; Hiraoka M; Inoue M; Tomatsu K; Hirano M; Mitsuhashi S
Drugs Exp Clin Res; 1989; 15(1):1-10. PubMed ID: 2663406
[TBL] [Abstract][Full Text] [Related]
10. Comparable evaluation of orally active beta-lactam compounds in ampicillin-resistant gram-positive and gram-negative rods: role of beta-lactamases on resistance.
Cullmann W; Dick W; Stieglitz M; Opferkuch W
Chemotherapy; 1988; 34(3):202-15. PubMed ID: 3262045
[TBL] [Abstract][Full Text] [Related]
11. The synthesis and biological evaluation of 7 beta-[2-(5-amino-[1,2,4] oxadiazol-3-yl)-2-Z-methoximinoacetamido]-cephalosporin derivatives.
Wheeler WJ; Deeter JB; Finley DR; Kinnick MD; Koehler R; Obsorne HE; Ott JT; Swartzendruber JK; Wishka DG
J Antibiot (Tokyo); 1986 Jan; 39(1):111-20. PubMed ID: 3485087
[TBL] [Abstract][Full Text] [Related]
12. [Research and development of new oral cephems, cefixime and cefdinir].
Sakane K; Kawabata K; Inamoto Y; Yamanaka H; Takaya T
Yakugaku Zasshi; 1993 Sep; 113(9):605-26. PubMed ID: 8229662
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of a new cephalosporin ME-1206 compared with other agents.
Chin NX; Zhang YX; Neu HC
Diagn Microbiol Infect Dis; 1991; 14(5):417-24. PubMed ID: 1797456
[TBL] [Abstract][Full Text] [Related]
14. Cefpodoxime: comparative antibacterial activity, influence of growth conditions, and bactericidal activity.
Knothe H; Shah PM; Eckardt O
Infection; 1991; 19(5):370-6. PubMed ID: 1800379
[TBL] [Abstract][Full Text] [Related]
15. In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus.
Jones ME
Clin Microbiol Infect; 2007 Jun; 13 Suppl 2():17-24. PubMed ID: 17488372
[TBL] [Abstract][Full Text] [Related]
16. Antibacterial activity of the investigational oral and parenteral cephalosporin BK-218.
Johnson DM; Jones RN
Eur J Clin Microbiol Infect Dis; 1992 Feb; 11(2):181-8. PubMed ID: 1396735
[TBL] [Abstract][Full Text] [Related]
17. In-vitro antibacterial activity of L-105, a new cephalosporin.
Hikida M; Inoue M; Mitsuhashi S
J Antimicrob Chemother; 1986 Nov; 18(5):585-91. PubMed ID: 3492485
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial activity and beta-lactamase stability of BMY-28232, parent compound of an oral cephalosporin.
Chin NX; Yu KW; Neu HC
Eur J Clin Microbiol Infect Dis; 1990 Nov; 9(11):841-6. PubMed ID: 2086221
[TBL] [Abstract][Full Text] [Related]
19. Antibacterial activity of BMY-28142, a novel broad-spectrum cephalosporin.
Tomatsu K; Ando S; Masuyoshi S; Hirano M; Miyaki T; Kawaguchi H
J Antibiot (Tokyo); 1986 Nov; 39(11):1584-91. PubMed ID: 3539901
[TBL] [Abstract][Full Text] [Related]
20. New orally active cephalosporin esters.
Yamada H; Ueda S; Mutoh M; Nagata H; Nouda H; Fukasawa M; Okuda T
J Antibiot (Tokyo); 1990 May; 43(5):578-83. PubMed ID: 2358409
[No Abstract] [Full Text] [Related]
[Next] [New Search]
